Position in REPL
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$1,315,310
New position
Shares Held
171,936
first reported quarter
Ownership
0.205%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026SILVERARC CAPITAL MANAGEMENT, LLC holds $784,099,188 across 56 Biotechnology names. REPL ranks #51 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KALV |
KalVista Pharmaceuticals, Inc.
|
2,876,407 | $57,902,072 | |
| 2 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
654,746 | $54,946,284 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
1,314,189 | $50,583,134 | |
| 4 | CELC |
Celcuity Inc.
|
357,903 | $40,851,048 | |
| 5 | IMNM |
Immunome Inc.
|
1,850,278 | $40,465,579 | |
| 6 | KOD |
Kodiak Sciences Inc.
|
991,930 | $37,812,371 | |
| 7 | NUVL |
Nuvalent, Inc.
|
354,914 | $36,360,939 | |
| 8 | ABVX |
Abivax S.A.
|
302,530 | $33,686,715 |
All Filings in REPL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,315,310 | 171,936 | Shares | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||